Ruxolitinib Switch-Maintenance Prophylaxis of GVHD

Randomized Pilot Study of Ruxolitinib for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation After Intermediate-Dose Post-Transplant Cyclophosphamide (Rux Switch-Maintenance in Intermediate PTCY: RuSMa-PTCY) in Comparison to Full-Dose PTCY

Near Add Your Location

Sorting 5 by

Center of Excellence

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Westchester
West Harrison, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Commack
Commack, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Nassau
Uniondale, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Bergen
Montvale, NJ
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.